Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TGFB2 serves as a link between epithelial-mesenchymal transition and tumor mutation burden in gastric cancer.

International immunopharmacology - 1 Jul 2020

Yang BoWen, Bai Jin, Shi Ruichuan, Shao Xinye, Yang Yujing, Jin Yue, Che Xiaofang, Zhang Ye, Qu Xiujuan, Liu Yunpeng, Li Zhi

Abstract excerpt

Immune checkpoint blockade (ICB) has been a major breakthrough in various cancers including gastric cancer (GC), yet the clinical outcomes remain poor. Currently, epithelial-mesenchymal transition (EMT) has been reported to be associated with tumor mutational burden (TMB), which can cause lack of response to ICB. However, the underlying mechanism remains unknown. Members of the transforming growth factorβ (TGFB)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epithelial-Mesenchymal Transition

Share to Gene Expression Regulation, Neoplastic

Share to Mutation

Share to Prognosis

Share to Stomach Neoplasms

Share to Transforming Growth Factor beta2

Source

Identifiers

PMID: 32388013
DOI: 10.1016/j.intimp.2020.106532

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TGFB2 serves as a link between epithelial-mesenchymal transition and tumor mutation burden in gastric cancer.PMID 32388013Read ↗

Association of the TGFβ gene family with microenvironmental features of gastric cancer and prediction of response to immunotherapySemantic proximity Read ↗

Identifcation and Validation of EMT-immune-related Prognostic Biomarkers CMTM3 and LTBP2 in Gastric CancerSemantic proximity Read ↗

Characterization of TGFβ-Associated Molecular Features and Drug Responses in Gastrointestinal AdenocarcinomaSemantic proximity Read ↗

Pan-Cancer Analysis of the Associations of TGFBI Expression With Prognosis and Immune CharacteristicsSemantic proximity Read ↗

Characterization of Tumor Mutation Burden-Based Gene Signature and Molecular Subtypes to Assist Precision Treatment in Gastric Cancer.Semantic proximity Read ↗

Tumor Mutation Burden: A Predictive Biomarker for Gastric Cancer ImmunotherapySemantic proximity Read ↗

Identification of TGF-β signaling-related molecular patterns, construction of a prognostic model, and prediction of immunotherapy response in gastric cancerSemantic proximity Read ↗

Identification of a Gene Prognostic Model of Gastric Cancer Based on Analysis of Tumor Mutation Burden.Semantic proximity Read ↗

Tumor mutation burden as a biomarker in resected gastric cancer via its association with immune infiltration and hypoxia.Semantic proximity Read ↗

Influence of Tumor Mutational Burden on Immune-infiltrating Cells in Stomach AdenocarcinomaSemantic proximity Read ↗

The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.Semantic proximity Read ↗

Significance of Tumor Mutation Burden Combined With Immune Infiltrates in the Progression and Prognosis of Advanced Gastric CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.